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Abstract 1 
 The specificity of the proteases of eleven retroviruses was studied using a series of 2 
oligopeptides having amino acid substitutions in P1, P3 and P4 positions of a naturally occurring 3 
type-1 cleavage site (Val-Ser-Gln-Asn-Tyr↓Pro-Ile-Val-Gln) in human immunodeficiency virus 4 
type-1 (HIV-1). Previously, substrate specificity for P2 site was studied of the same representative 5 
set of retroviral proteases, which included at least one member from each of the seven genera of 6 
the family Retroviridae (Bagossi, P., T. Sperka, A. Feher, J. Kadas, G. Zahuczky, G. Miklossy, P. 7 
Boross, and J. Tozser. 2005. J. Virol. 79:4213-4218). Our enzyme set composed the proteases of 8 
HIV-1, HIV-2, equine infectious anemia virus, avian myeloblastosis virus, Mason-Pfizer monkey 9 
virus (MPMV), mouse mammary tumor virus (MMTV), Moloney murine leukemia virus, human T-10 
lymphotropic virus type 1, bovine leukemia virus, human foamy virus and walleye dermal sarcoma 11 
virus. Molecular models were used to interpret the specificity similarities and differences between 12 
these retroviral proteases. The results showed that retroviral proteases had similar preferences 13 
(Phe, Tyr) for the P1 position in this sequence context, but more differences were found for the 14 
P3 and P4 positions. Importantly, the size of the P3 and P4 residues appear to be a major 15 
contributor for specificity. The substrate specificities correlated well with the phylogenetic tree of 16 
retroviruses. Furthermore, while the specificity of some enzymes belonging to different genera 17 
appeared to be very similar (e.g. that of AMV and MMTV), the specificity of primate lentiviral 18 
proteases substantially differed from that observed for a nonprimate lentiviral protease.   19 
 20 
 3 
Introduction  1 
 Infection by retroviruses, most notably human immunodeficiency virus (HIV), causes 2 
severe immunodeficiency, cancer, and anemia in humans and in many economically important 3 
vertebrates. With the exception of HIV/AIDS, relatively few studies have focused on human 4 
diseases arising from retroviral infections.   5 
 The total number of people living with HIV has continued to increase and it is estimated to 6 
be about 33 million people in the world (36). There were more than 2 million new infections, and 7 
about 2 million people died of acquired immunodeficiency syndrome (AIDS) related illnesses in 8 
2007 (36). Antiretroviral therapies have proved to be effective since the introduction of the 9 
combination of drugs including inhibitors of the retroviral protease (PR). The PR of HIV is an 10 
excellent target for chemotherapy (for reviews, see references (16, 33)), since the PR activity is 11 
essential for the maturation and infectivity of the virus (as reviewed in references (14, 21)). 12 
Specificity studies of wild type and mutant HIV PRs have provided a basis for the rational design 13 
of potent, selective inhibitors (4, 30, 38) and also may help to circumvent the problems caused by 14 
the rapidly developing resistance against the compounds used in therapy (28).  15 
 Human T-lymphotropic virus (HTLV) infection is also a global epidemic: 10–20 million 16 
individuals are estimated to be carriers of the virus, and the risk of developing disease is 17 
estimated to be 5% in infected patients (15). HTLV-1 has been etiologically associated with a 18 
number of diseases including adult T-cell leukemia and HTLV-1 associated myelopathy (10). 19 
Studies indicate that viral replication is critical for the development of HTLV-1 associated 20 
myelopathy, and initial studies suggested that blocking replication with AZT had a therapeutic 21 
effect (26). HTLV PR inhibitors may also have therapeutic value in the HTLV-associated 22 
diseases, similar to the successful application of HIV PR inhibitors to treat AIDS.  23 
 4 
 Another retrovirus, which can infect people, is the human foamy virus (HFV) or prototype 1 
foamy virus (PFV). Retroviruses of the foamy virus subgroup have several unusual features (8, 2 
23), but the PR of the HFV is also essential for viral infectivity (11). HFV holds great promise in 3 
gene therapy (20), because of its inability to cause pathogenic disease (12). However, such an 4 
application requires detailed knowledge of the replication strategy as well as the enzymes of this 5 
virus. 6 
 Retroviral PR cleavage sites are currently classified into two major groups (reviewed in 7 
(33)). Type-1 cleavage sites have an aromatic residue and Pro, while type-2 cleavage sites have 8 
hydrophobic residues (excluding Pro) at the site of cleavage. Other positions, especially P2 and 9 
P2’ (nomenclature is according to reference (25)), also substantially contribute to the specificity 10 
and showed significant differences in terms of preference in the two types of cleavage sites.  11 
 Comparative study of divergent members of the retroviral PR family is a promising 12 
approach not only to recognize general and specific features of the PR, but also to discover the 13 
mutational capacity of the PR. Several of the mutations causing drug resistance of HIV-1 PR 14 
introduce residues into the substrate binding sites that are found in the equivalent position of 15 
other retroviruses (13, 24). Retroviral PRs can recognize at least seven residues of the substrates, 16 
which bind to the enzyme in an extended conformation, as schematically shown in Fig. 1. 17 
Previously, a large set of peptides containing single amino acid substitutions in the P4-P3' region 18 
of the Val-Ser-Gln-Asn-Tyr↓Pro-Ile-Val-Gln oligopeptide, a typical type-1 substrate (where the 19 
arrow denotes the site of cleavage) was used to characterize the specificity of the PR of various 20 
retroviruses including HIV-1, HIV-2 (32, 34), equine infectious anemia virus (EIAV) (37), 21 
Moloney murine leukemia virus (MMLV) (18) and avian myeloblastosis virus (AMV) (31). Based 22 
on these studies, the P2 position was found to be critical for determining the substrate specificity 23 
 5 
differences of retroviral proteases. Therefore, the P2 position was characterized in the first part of 1 
our study (1). Here, we have continued with studies of the specificity of P1, P3 and P4 positions 2 
using the same PR set previously utilized for the mapping of the P2 position, comprising at least one 3 
member of each genera of the family Retroviridae including HIV-1, HIV-2, EIAV, MMLV, AMV, 4 
Mason-Pfizer monkey virus (MPMV), mouse mammary tumor virus (MMTV), HTLV-1, bovine 5 
leukemia virus (BLV), HFV and walleye dermal sarcoma virus (WDSV) proteases. Our previous (1) 6 
and present study has the advantage that the different retroviral proteases were mapped with the 7 
same peptide series in the same reaction conditions in the same laboratory, therefore the results are 8 
directly comparable.  9 
 10 
Materials and methods 11 
Retroviral proteases 12 
 Chemically synthesized HIV-2 PR was purified and refolded as described (34). Purified 13 
MPMV PR (the shortest, 12 kDa form) was prepared as described previously (39). MMTV protease 14 
was expressed as a GST-fusion protein, processed with Factor Xa and purified following the 15 
published procedure (19). MMLV protease was cloned with MBP and hexahistidine tags and 16 
purified as described (6). HTLV-1 protease (13), BLV protease (40) and WDSV protease (9) were 17 
purified from inclusion bodies after expression as described previously. HFV protease was cloned in 18 
fusion with MBP and it was used in its fusion form (7). The activity of MBP-fusion form of HFV 19 
protease was similar to that of the processed form  (3). 20 
 21 
Oligopeptides  22 
 6 
 Oligopeptides synthesized by solid-phase peptide synthesis were described previously (17, 1 
19, 34). Stock solutions and dilutions were made in distilled water (or in 5 mM dithiothreitol for 2 
the Cys-containing peptide), and the proper peptide concentrations were determined by amino 3 
acid analysis.   4 
 5 
Protease assay  6 
 Protease assays were performed at 37 °C using purified retroviral proteases and chemically 7 
synthesized oligopeptides (0.4 mM) in 0.25 M potassium phosphate buffer, pH 5.6, containing 8 
7.5% glycerol, 5 mM dithiothreitol, 1 mM EDTA, 0.2% Nonidet P-40 and 2 M NaCl. The 9 
reaction mixtures were incubated at 37 °C for one hour or 24 hours in case of HFV and WDSV 10 
proteases, and were stopped by the addition of 9 volumes 1 % trifluoroacetic acid (TFA) then 11 
injected onto a Nova-Pak C18 reversed-phase chromatography column (3.9 x 150 mm, Waters 12 
Associates, Inc.) using an automatic injector. Substrates and the cleavage products were separated 13 
using acetonitrile gradient (0-100%) in water, in the presence of 0.05% TFA. The cleavage of 14 
peptides was monitored at 206 nm, and the peak areas were integrated. Amino acid analysis of the 15 
collected peaks was used to confirm the site of cleavage with HIV-1 PR (34). For the other 16 
retroviral proteases the cleavage products were identified by the retention time, which was found to 17 
be identical to that obtained with HIV-1 PR. Relative activities were calculated from the molar 18 
amounts of peptides cleaved per unit time at less than 20% substrate turnover, by dividing the 19 
activity on a given peptide by the activity on the reference substrate, as described (1, 2). 20 
Measurements were performed in duplicate and the average values were calculated. The standard 21 
error was less than 10%. The relative activities for the HIV-1 PR (34), EIAV PR (37) and AMV PR 22 
(31) have been reported previously.  23 
 7 
 1 
Molecular modeling  2 
 The sequence alignment of the proteases used in this study and the construction of molecular 3 
models were described previously (1). A model of VSQNY↓PIVQ oligopeptide was docked into the 4 
substrate binding site of each retroviral protease and the minimization and analysis procedure were 5 
applied as described (1) with the Sybyl program package (Tripos Inc., St. Loius, MO, USA) run on 6 
the Silicon Graphics Fuel computer graphics system. Sequence identity and similarity percentage 7 
values for the full protease sequences as well as for the set of residues involved in the substrate 8 
binding (18-20 residues of the proteases) are provided in the Supplemental Table 1.  Cavities were 9 
calculated from the minimized structures containing Gly at P1, P3 or P4 position using the SiteID 10 
modul of Sybyl.  It should be noted that the calculated cavity volumes are comparable only for a 11 
given subsite and not suitable for comparison of different subsites, as a consequence of the 12 
cavity-finding algorithm of SiteID program and the diverse solvent accessibility of the binding 13 
sites (e.g. S1 is fully buried while S4 is opened to the surface). The volume of the amino acid 14 
residues was retrieved from the literature (41).  15 
 16 
Results  17 
 Substrate specificity of the S1 subsite of retroviral proteases 18 
 Results obtained with representative P1-modified substrates are visualized in Fig. 2, and the 19 
complete set of relative activity values is provided in the Table 2 of the Supplemental material. 20 
None of the substrates were cleavable by HTLV-1 and HFV proteases. For the other enzymes, the 21 
activities were calculated relative to those obtained with the original, P1 Tyr-containing substrate. 22 
The S1 binding site of the PRs appears to be hydrophobic. The HIV-1, HIV-2, EIAV, AMV, 23 
 8 
MMLV and WDSV proteases shared similar specificity, showing the preference order of Phe > 1 
Tyr > Leu ≅ Met > Ala, although the individual values for relative activity showed some 2 
variation. MPMV and MMTV PRs were more selective for the large aromatic residues. On the 3 
other hand, the PR of BLV showed the highest preference for Leu at P1, followed by Phe or Met. 4 
Therefore, the S1 site is large, hydrophobic and well conserved among retroviral proteases. These 5 
results agree with predictions from the molecular models that a bulky hydrophobic P1 side chain 6 
will fill the S1 subsite to obtain efficient cleavage. However, there are some fine specificity 7 
distinctions, in terms of whether the enzymes would also favor (or tolerate) smaller residues at 8 
this position. HIV-1, HIV-2, EIAV, AMV, MMLV and WDSV proteases tolerated the smaller 9 
Leu and Met residues substantially better than did MPMV and MMTV proteases (Fig. 2, Table 2 10 
of Supplemental material). Interestingly, in the case of HIV-1 PR a similar preference order of 11 
Phe >> Met ≅ Tyr ≅ Leu was observed using another substrate set (Lys-Thr-Lys-Val-Xaa↓Val-12 
Val-Gln-Pro-Lys) based on the HTLV-1 CA/NC (typical type-2) cleavage site (35), while HTLV-1 13 
and BLV proteases preferred Phe > Leu > Tyr > Ala and Tyr ≅ Phe > Leu ≅ Met, respectively (27). 14 
The strong sequence context dependence of the preference at a given site was recognized earlier 15 
(reviewed in (33)). 16 
 17 
Substrate specificity of the S3 subsite of retroviral proteases  18 
 Unlike the S1 subsite, various residues were preferred when the S3 binding sites were 19 
mapped for different retroviral PRs (Fig. 3). The complete set of relative activity values is 20 
provided in the Table 3 of the Supplemental material. The HIV and EIAV PRs preferred the 21 
original polar Gln at P3 (Fig. 3), but the second best residue was a hydrophobic one (Val for HIV-22 
1 and HIV-2 PRs, Phe for EIAV PR). Smaller residues (Gly and Ala) were also well tolerated. A 23 
 9 
pronounced preference for the large hydrophobic residues, Phe and Leu, characterized AMV, 1 
MPMV and MMTV proteases. In fact, MMTV PR did not hydrolyze the substrates with Gly or 2 
Ala at P3. Also, MPMV PR was unusual in recognizing Asp at P3 in this substrate. On the other 3 
hand, the small Ala, as well as the polar Lys were preferred by the BLV PR, and Gly by the 4 
WDSV PR (Fig. 3). The size of the residue appears to be the main specificity determinant at this 5 
position, since, with the exception of the WDSV PR, the size of the average volume of the two 6 
most preferred P3 residues correlated well with the mean cavity of the S3 subsite of the enzymes 7 
(Fig. 4), as previously established for the P2 position (1). In the exceptional case of WDSV 8 
protease, the S3 subsite binding pocket that was predicted to be relatively large and less suitable 9 
for small residues at P3. However, the uncertainty of the model of WDSV protease may 10 
contribute to this discrepancy.   11 
 12 
Substrate specificity of the S4 subsite of retroviral proteases 13 
 Various residues were found to fit preferably to the S4 sites of the PRs, similar to the results 14 
for S3, as indicated by Fig. 5. The activities were calculated relative to that of the P4 Val-15 
containing substrate instead of the original Ser-containing one, since the former was also a 16 
substrate of the HTLV-1 PR. The complete data are provided in the Table 4 of the Supplemental 17 
material. In the case of primate lentiviral proteases, like HIV-1 and HIV-2 proteases, the polar Ser 18 
as well as the smaller Gly or Ala residues are strongly preferred. EIAV PR prefers hydrophobic 19 
residues Val, Leu, Phe and Pro. AMV, MPMV and MMTV proteases preferred medium-sized or 20 
large hydrophobic residues Ile, Leu and Phe (Fig. 5). In contrast, the BLV and WDSV proteases 21 
preferred small hydrophobic residues (Ala, Pro) at P4, while MMLV protease preferred medium-22 
sized polar (Ser, Thr, Asp) residues (Fig. 5). However, this subsite lies at the PR surface, and 23 
 10 
lacks the well-defined pocket of the internal subsites. For many of these PRs a correlation was 1 
observed between the size of the average volume of the best two residues and the mean cavity of 2 
the S4 subsite of the enzymes, similar to the results for S3. However, HIV-1 and MMLV PRs did 3 
not fit this correlation for S4 (Fig. 6), that could be due to the less well defined S4 subsites of 4 
these proteases suggested by the molecular models. 5 
 6 
Discussion 7 
 These results, together with the previously published analysis of the S2 subsite, provide a 8 
basis for characterization of the specificity of the amino-terminal subsites (S4-S1) of retroviral 9 
proteases using a type-1 cleavage site substrate, having Tyr and Pro at the site of cleavage. A 10 
schematic representation of the specificities is provided in Fig. 7. The alpharetroviral AMV and 11 
betaretroviral MMTV proteases appear to share very similar specificity. All their substrate 12 
binding sites are hydrophobic and large, except for the small S2 pocket (Fig. 7). The 13 
deltaretroviral BLV PR has large hydrophobic S1 and S2 pockets, and smaller S3 and S4 subsites, 14 
and only the S3 subsite has some polar character. The gammaretroviral MMLV PR has a similar 15 
specificity, except the S4 site appears to be small and hydrophilic. On the other hand, the 16 
epsilonretroviral WDSW PR has hydrophobic S4, S1, and somewhat hydrophilic S2 and S3 17 
subsites. Interestingly, the specificity of lentiviral proteases can be subdivided into two groups. 18 
The primate lentiviral HIV-1 and HIV-2 PRs have a substantially different specificity as 19 
compared to that of the EIAV PR, both in the hydrophobicity of the S2 and S4 subsites as well as 20 
the size of S4. The important conclusion is that the specificity pattern of the subsites agrees with 21 
the evolutionary relationship among the proteases as represented by the phylogenetic tree (Fig 7). 22 
For example, EIAV, AMV and MMTV share very similar specificity at S1, S2 (1) and S4 23 
 11 
subsites. It is of interest to note that while the degree of sequence identity and similarity of 1 
retroviral protease sequences is fairly low, the residues forming the substrate binding sites are 2 
substantially more conserved (Supplemental Material, Table 1), a likely consequence of the 3 
selective evolutionary pressure to maintain these residues as compared to those that are not 4 
critical for the structure and activity of the enzyme.  5 
 HIV-1 PR clinical inhibitors typically only weakly inhibit, if at all, the other retroviral 6 
proteases, with the exception of MMLV PR, which was inhibited by an HIV-1 PR inhibitor (5). 7 
So there is an apparent contradiction between the relatively conserved substrate specificity among 8 
retroviral PRs and an almost complete lack of inhibition by HIV-1 PR inhibitors. This 9 
contradiction might be due to the fact that the clinical inhibitors are typically rigid molecules, 10 
while substrates are more flexible, and capable of adapting to altered substrate binding sites in 11 
different retroviral PRs. The same phenomenon is observed in drug resistant HIV-1 PR variants 12 
(22, 29). The development of resistance towards the drugs designed against HIV-1 PR is one of the 13 
main problems in the protease inhibitor therapy of AIDS. Many of the mutations occurring in drug 14 
resistance introduce amino acids that can be found at the equivalent position in other retroviral 15 
proteases. Therefore, characterization of the specificity similarities and differences of these enzymes 16 
may help to design broad-spectrum inhibitors against HIV-1 PR. 17 
 18 
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Figure legends 1 
Figure 1. A schematic representation of the HIV-1 matrix↓capsid substrate in the S4-S3’ subsites 2 
of HIV-1 PR. The relative size of each subsite is indicated approximately by the area enclosed by 3 
the curved line around each substrate side chain.  4 
Figure 2. Comparison of relative activities obtained on selected Val-Ser-Gln-Asn-Xaa↓Pro-Ile-5 
Val-Gln peptides for retroviral proteases. 6 
Figure 3. Comparison of relative activities obtained on selected Val-Ser-Xaa-Asn-Tyr↓Pro-Ile-7 
Val-Gln peptides for retroviral proteases. 8 
Figure 4. Mean cavity volume of the S3 subsite of various retroviral proteases versus averaged 9 
volume of the two P3 residues for which the measured relative activity was the highest.  10 
Figure 5. Comparison of relative activities obtained on selected Val-Xaa-Gln-Asn-Tyr↓Pro-Ile-11 
Val-Gln peptides for retroviral proteases. 12 
Figure 6. Mean cavity volume of S4 subsite of various retroviral proteases versus averaged volume 13 
of the two P4 residues for which the measured relative activity was the highest.  14 
Figure 7. Phylogenetic tree and schematic representation of the preferred residues of the S4-S1 15 
subsites of representative retroviral proteases. The phylogenetic tree contains Rous sarcoma virus 16 
(RSV) PR while measurements were performed using AMV PR. These two PRs differ only in two 17 
residues that do not influence the specificity. The size of the oval objects representing the substrate 18 
amino acid side chains approximates the size of the most preferred residues. Gray objects represent 19 
sites that prefer predominantly hydrophobic residues, while white objects represent sites that do not 20 
discriminate based on hydrophobicity. Dashed lines for the S4 subsites indicate that these pockets 21 
are less defined than the other ones, due to the proximity to the protein surface. 22 
 19 
Eizert et al., Fig. 1.  1 
 2 
 3 
 20 
Eizert et al., Fig. 2. 1 
HIV-1 HIV-2 EIAV AMV MPMV MMTV MMLV BLV WDSV
r
e
l
a
t
i
v
e
 
a
c
t
i
v
i
t
y
 
(
X
a
a
/
T
y
r
)
0.01
0.1
1
10
100
Ala
Leu
Met
Phe
Tyr
 2 
 3 
 21 
Eizert et al., Fig. 3.   1 
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Eizert et al., Fig. 4 1 
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Eizert et al., Fig. 5.  2 
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Eizert et al., Fig. 6.  1 
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Eizert et al., Fig. 7.  1 
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Supplemental Material, Table 1. Sequence identity and similarity of retroviral proteases. 1 
____________________________________________________________________________________ 2 
 PR HIV-1   HIV-2    EIAV    AMV   MPMV   MMTV   MMLV   HTLV-1   BLV  WDSV   HFV 3 
____________________________________________________________________________________ 4 
HIV-1       --       --  --     --         --             --      --         --          --        --   -- 5 
HIV-2 47/63       --  --     --         --             --          --               --             --        --   -- 6 
 65/80       7 
EIAV 31/40    36/46 --     --         --     --          --         --             --        --           -- 8 
                   70/75    55/75        9 
AMV 31/41    26/40     27/45     --         --     --          --         --             --        --          -- 10 
                   50/55    50/55     45/60                    11 
MPMV       24/39    22/36     20/37     25/41     --            --            --              --             --          --          -- 12 
                   50/75    45/65     40/75     40/70                        13 
MMTV 22/32     20/31     22/37     24/38     46/57      --            --              --            --        --           -- 14 
                   45/65    40/55     40/65     35/60     55/65      15 
MMLV 24/41     24/36     24/35     16/33     21/32    16/30        --         --    --           --           -- 16 
                   40/50    35/45     40/50     25/40     35/50    40/55   17 
HTLV-1 34/42     26/40     29/42     24/37     20/33    18/27      22/29         --    --           --           -- 18 
                   50/55    45/50     50/55     40/50     30/55    40/55      45/55 19 
BLV 28/45     22/39     25/38     22/34     17/30    15/27      27/36     32/43    --        --   -- 20 
                   45/55    40/50     45/55     35/50     25/55     30/50     55/60     75/85     21 
WDSV 15/26     19/32     22/29     17/28     19/28     18/32     22/34     19/29     13/21        --           -- 22 
                   35/35    40/40     30/35     35/40     35/45     30/40     25/35     30/40     30/35      23 
HFV 23/30     16/30     15/25     22/28     12/20     10/19     15/21     17/26     18/27     14/22       -- 24 
                   35/35    25/40     25/30     30/30     25/40      20/30    15/20     15/25     15/20      25/40 25 
___________________________________________________________________________________ 26 
Sequence identity and similarity of full retroviral protease sequences as well as of residues involved in 27 
substrate binding (numbers in bold) are given as identity/similarity percentage values.  28 
 27 
Supplemental material, Table 2. Relative activities obtained on Val-Ser-Gln-Asn-Xaa↓Pro-Ile-Val-Gln peptides for retroviral proteases. 1 
_________________________________________________________________________________________________________________ 2 
          Lentivirus1   Alpha-     Betaretrovirus  Gamma-   Deltaretrovirus      Epsilon-      Spuma- 3 
                retrovirus     retrovirus         retrovirus      virus 4 
                                                                                                                                                                                                         5 
                  Protease of 6 
P1 residue  HIV-1 HIV-2 EIAV AMV MPMV MMTV MMLV HTLV-1 BLV      WDSV        HFV 7 
_________________________________________________________________________________________________________________ 8 
Gly   0  0  0  0  0  0  0  0  nd2  0  0 9 
Ala   0.01  0  0  0.01  0  0  0  0  0.27  0  0 10 
Val   0  0  0  0.02  0  0  0  0  0.13  0  0 11 
Leu   0.21  0.25  0.09  0.21  0.03  0.01  0.91  nd  10  0.30  0 12 
Phe   1.7  1.3  1.4  1.6  2.1  1.3  8.2  0  7.6  1.8  0 13 
Tyr   1  1  1  1  1  1  1  0  1  1  0 14 
Trp   0.01   nd  0  0.02  0  0  0  0  0.18  0  0 15 
Cys   <0.01 nd  0.69  <0.01 0  nd  0  0  0.86  nd  0 16 
Met   0.23  0.40  0.15  0.17  0.02  0.01  0.70  0  6.8  0.51  0 17 
Ser   0  0  0  0  0  0  0  0  0  0  0 18 
Asp   0  0  0  0  0.02  0  0  nd  0  0  0 19 
Lys   0  0  0  0  0  0  0  0  0  0  0 20 
_________________________________________________________________________________________________________________ 21 
1Classification is based on the latest report of the International Committee on Taxonomy of Viruses (ICTV), as detailed at the ICTV database 22 
(http://www.ncbi.nlm.nih.gov/ICTVdb). Activities were expressed relative to that obtained with the Val-Ser-Gln-Asn-Tyr↓Pro-Ile-Val-Gln 23 
substrate, except for HTLV-1 and HFV PRs.  2nd, not determined. The best two values are highlighted in bold. 24 
 28 
Supplemental Material, Table 3. Relative activities obtained on Val-Ser-Xaa-Asn-Tyr↓Pro-Ile-Val-Gln peptides for retroviral proteases.  1 
_________________________________________________________________________________________________________________ 2 
          Lentivirus1   Alpha-     Betaretrovirus  Gamma-   Deltaretrovirus      Epsilon-      Spuma- 3 
                retrovirus     retrovirus         retrovirus      virus 4 
                                                                                                                                                                                                         5 
                  Protease of 6 
P3 residue  HIV-1 HIV-2 EIAV AMV MPMV MMTV MMLV HTLV-1 BLV      WDSV        HFV 7 
_________________________________________________________________________________________________________________ 8 
Gly   0.18  0.23  0.21  0.03  0.59  0  0.18  0  0.23  0.67  0 9 
Ala   0.34  0.30  0.14  0.42  0.51  0  0.55  0  1.8  0.42  0 10 
Val   0.71  0.64  0.01  0.50  0.46  1.4  0.02  0  0.23  0.32  nc2 11 
Leu   0.09  0.42  0.01  2.0  1.0  4.8  0.10  0  0.28  0.35  0 12 
Phe   0.22  0.13  0.23  2.4  1.3  7.5  0.77  0  0.05  0.11  0 13 
Asn   0.50  0.32  0.08  0.05  0.43  1.1  0.81  0  0.26  0.11  0 14 
Gln   1  1  1  1  1  1  1  0  1  1  0 15 
Asp   0.01  0.10  0  0.01  0.81  0.06  0.01  0  0.22  0  0 16 
Lys   0.12  0.16  0.01  0.07  0.07  0.51  0.40  0  1.7  0.34  0 17 
_________________________________________________________________________________________________________________ 18 
1Classification is based on the latest report of the International Committee on Taxonomy of Viruses (ICTV), as detailed at the ICTV database 19 
(http://www.ncbi.nlm.nih.gov/ICTVdb). Activities were expressed relative to that obtained with the Val-Ser-Gln-Asn-Tyr↓Pro-Ile-Val-Gln 20 
substrate, except for HFV PR for which only one peptide was cleaved. The best two values are highlighted in bold. 2nc, not calculated. It 21 
should be noted, that in case of HFV, only the P3 Val-containing peptide was hydrolyzed, therefore it was not possible to calculate the 22 
relative activity value.  23 
  24 
 29 
Supplemental Material, Table 4. Relative activities obtained on Val-Xaa-Gln-Asn-Tyr↓Pro-Ile-Val-Gln peptides for retroviral proteases.  1 
_________________________________________________________________________________________________________________ 2 
          Lentivirus1   Alpha-     Betaretrovirus  Gamma-   Deltaretrovirus      Epsilon-      Spuma- 3 
                retrovirus     retrovirus         retrovirus      virus 4 
                                                                                                                                                                                                         5 
                  Protease of 6 
P4 residue  HIV-1 HIV-2 EIAV AMV MPMV MMTV MMLV HTLV-1 BLV      WDSV        HFV 7 
_________________________________________________________________________________________________________________ 8 
 9 
Gly   15  27  0.09  0.02  0.11  0.08  16  0  0.03  0.10  0 10 
Ala   6.0  10  0.86  0.24  0.57  0.56  14  0  1.2  1.9  0 11 
Val   1  1  1  1  1  1  1  1  1  1  0 12 
Ile   0.60  1.0  0.86  2.1  1.7  2.2  6.7  0.92  0.07  1.4  0 13 
Leu   0.40  2.0  1.1  1.2  2.4  0.64  3.3  nd  0  1.0  0 14 
Phe   0.60  0.33  0.93  1.1  3.1  4.4  8.0  0.77  0  1.0  0 15 
Met   0.80  7.3  0.46  0.64  1.3  0.72  18  0.38  0  1.0  0 16 
Ser   20  33  0.71  0.11  0.29  0.40  33  0  1.1  0.43  0 17 
Thr   5.4  19  0.24  0.53  0.43  nd  26  0  1.0  0.48  0 18 
Pro   2.8  4.0  1.4  0.68  0.34  nd  15  1.7  1.6  1.3  0 19 
Asn   3.4  nd  0.49  0.15  0.34  0.23  10  nd  0.03  0.43  0 20 
Asp   3.4  21  0.49  0.09  0.13  0.14  23  0  0  0.03  0 21 
Lys   1.2  1.0  0.18  0.32  2.1  0  7.3  0  0.01  1.0  0 22 
_________________________________________________________________________________________________________________ 23 
1Classification is based on the latest report of the International Committee on Taxonomy of Viruses (ICTV), as detailed at the ICTV database 24 
(http://www.ncbi.nlm.nih.gov/ICTVdb). Relative activities were expressed as activity relative to that obtained with the Val-Val-Gln-Asn-25 
Tyr↓Pro-Ile-Val-Gln substrate. The best two values are highlighted in bold.  26 
